Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001431" target="_blank" >RIV/00064190:_____/25:10001431 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00143792
Result on the web
<a href="https://doi.org/10.1038/s41598-025-32593-8" target="_blank" >https://doi.org/10.1038/s41598-025-32593-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41598-025-32593-8" target="_blank" >10.1038/s41598-025-32593-8</a>
Alternative languages
Result language
angličtina
Original language name
Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab
Original language description
The role of eosinophils in patients with cancer receiving systemic therapy based on immune checkpoint inhibitors (ICIs) has become a subject of increasing interest. The aim of the present study was to assess the prognostic role of absolute eosinophil count (AEC) and neutrophil-to-eosinophil ratio (NER) in patients with metastatic renal cell carcinoma (mRCC) receiving nivolumab. The associations of AEC and NER at baseline and their relative changes (Delta) after one month of nivolumab therapy with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analyzed. In total, 458 patients were included. Baseline AEC >= 70 cells/mu L (PFS: HR: 0.663, p = 0.009; OS: HR: 0.583, p = 0.002), AEC one month after nivolumab initiation >= 70 cells/mu L (PFS: HR: 0.544, p = 0.001; OS: HR: 0.331, p < 0.001) and NER < 65 one month after nivolumab initiation (PFS: HR: 0.552, p < 0.001; OS: HR: 0.326, p < 0.001) was associated with superior PFS and OS, and baseline NER < 65 was associated with superior OS (HR: 0.664, p = 0.014). Regarding early dynamics, Delta NER >= 125% was associated with inferior PFS (HR: 1.950, p = 0.001) and OS (HR: 2.680, p < 0.001), and Delta AEC <-30% was associated with inferior OS (HR: 2.132, p < 0.001). Higher ORR was associated with baseline AEC >= 70 cells/mu L (p = 0.048), baseline NER < 65 (p = 0.010); and NER one month after nivolumab initiation < 65 (p = 0.025). The results of the present study suggest that eosinophil-based blood parameters including AEC and NER and their early dynamics during the course of treatment with nivolumab are promising and readily available prognostic biomarkers in patients with mRCC.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10700 - Other natural sciences
Result continuities
Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
SCIENTIFIC REPORTS
ISSN
2045-2322
e-ISSN
—
Volume of the periodical
16
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
12
Pages from-to
nestránkováno
UT code for WoS article
001667610600001
EID of the result in the Scopus database
2-s2.0-105028305510